Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Girentuximab (Primary)
- Indications Renal cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Heidelberg Pharma AG
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 13 Jun 2013 Study title is not official; assumed registrational.
- 13 Jun 2013 New trial record